Residual Thromboembolic Risk and Outcomes of Oral Anticoagulation Discontinuation After Atrial Fibrillation Ablation: A Target Trial Emulation

Europace · Published 2026-08-03 · DOI 10.1093/europace/euag197

Free full text

Authors (20)

Xiaodong Peng, Liu He, Jue Wang, Sitong Li, Qifan Li, Zixu Zhao, Zejun Yang, Mingxiao Li, Fadong Li, Xiaoxia Liu, Song Zuo, Xueyuan Guo, Junmeng Zhang, Ning Zhou, Yunlong Wang, Deyong Long, Caihua Sang, Xin Du, Jianzeng Dong, Changsheng Ma

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Peng, X., He, L., Wang, J., et al. (2026). Residual Thromboembolic Risk and Outcomes of Oral Anticoagulation Discontinuation After Atrial Fibrillation Ablation: A Target Trial Emulation. Europace. https://doi.org/10.1093/europace/euag197

Related articles